Ting Li1, Xiang-Ling Meng2, Wen-Qi Yang2. 1. Department of the First Ward of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei City, 230022, Anhui Province, China. tingli_022@163.com. 2. Department of the First Ward of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei City, 230022, Anhui Province, China.
Abstract
BACKGROUND: PVT1 was up-regulated in patients with gastric cancer (GC) and might be as a novel biomarker for predicting GC. However, the exact mechanism of PVT1 exerting functions in GC was still poorly understood. Emerging evidence suggests that long noncoding RNAs may act as endogenous microRNA (miRNA) sponges to bind to miRNAs and regulate their function. AIM: This study aimed to determine the function of PVT1 on miR-152 expression in GC cells. METHODS: The levels of PVT1 and miR-152 were determined in GC tissues by quantitative real-time PCR. The expression of miR-152 was detected in GC cells transfected with PVT1 plasmid or siPVT1. Luciferase assay was performed to verify the regulation of miR-152 to CD151 or FGF2 expression and PVT1 to miR-152 expression. The effects of PVT1 on the expression of CD151 and FGF2 were evaluated by Western blot. RESULTS: PVT1 was up-regulated in GC tissues than that in the matched normal tissues, and mRNA level of miR-152 was decreased. MiR-152 was negatively associated with PVT1 expression in GC tissues. Based on the in silico analysis, we found that PVT1 have three binding sequences for miR-152. Moreover, PVT1 might inhibit the expression of miR-152 and increased the expression of CD151 and FGF2 through regulating miR-152. PVT1 was positively associated with CD151 and FGF2 expression in GC tissues. CONCLUSIONS: PVT1 might act as a "sponge" to inhibit miR-152 in gastric cancer cells. PVT1 is a promising molecular target to improve the diagnosis and therapy of GC.
BACKGROUND:PVT1 was up-regulated in patients with gastric cancer (GC) and might be as a novel biomarker for predicting GC. However, the exact mechanism of PVT1 exerting functions in GC was still poorly understood. Emerging evidence suggests that long noncoding RNAs may act as endogenous microRNA (miRNA) sponges to bind to miRNAs and regulate their function. AIM: This study aimed to determine the function of PVT1 on miR-152 expression in GC cells. METHODS: The levels of PVT1 and miR-152 were determined in GC tissues by quantitative real-time PCR. The expression of miR-152 was detected in GC cells transfected with PVT1 plasmid or siPVT1. Luciferase assay was performed to verify the regulation of miR-152 to CD151 or FGF2 expression and PVT1 to miR-152 expression. The effects of PVT1 on the expression of CD151 and FGF2 were evaluated by Western blot. RESULTS:PVT1 was up-regulated in GC tissues than that in the matched normal tissues, and mRNA level of miR-152 was decreased. MiR-152 was negatively associated with PVT1 expression in GC tissues. Based on the in silico analysis, we found that PVT1 have three binding sequences for miR-152. Moreover, PVT1 might inhibit the expression of miR-152 and increased the expression of CD151 and FGF2 through regulating miR-152. PVT1 was positively associated with CD151 and FGF2 expression in GC tissues. CONCLUSIONS:PVT1 might act as a "sponge" to inhibit miR-152 in gastric cancer cells. PVT1 is a promising molecular target to improve the diagnosis and therapy of GC.
Entities:
Keywords:
CD151; FGF2; Gastric cancer; Long noncoding RNA; MiR-152; PVT1
Authors: Y Takahashi; G Sawada; J Kurashige; R Uchi; T Matsumura; H Ueo; Y Takano; H Eguchi; T Sudo; K Sugimachi; H Yamamoto; Y Doki; M Mori; K Mimori Journal: Br J Cancer Date: 2013-11-05 Impact factor: 7.640
Authors: Kevin Tabury; Mehri Monavarian; Eduardo Listik; Abigail K Shelton; Alex Seok Choi; Roel Quintens; Rebecca C Arend; Nadine Hempel; C Ryan Miller; Balázs Györrfy; Karthikeyan Mythreye Journal: Life Sci Alliance Date: 2022-07-12